Background & Aims: Chimeric Antigen Receptor (CAR) T-cell
therapy is a novel anti-cancer treatment option for patients with
refractory or relapsed haematological malignancies. Preliminary
research shows a significant proportion of patients receiving CAR
T-cell therapy develop malnutrition and cachexia during treatment, with these nutritional issues associated with adverse patient
outcomes. There is a lack of literature and no specific validated
measures on patient experience and burden of symptoms for CAR
T-cell therapy patients as well as the importance of clinical outcomes for these patients. Patient and public involvement (PPI) is a
fundamental feature of proper research execution as it informs
issues in the research that are most important in patients. The aim
of this review was to identify priority patient-reported outcome
measures in CAR T-cell therapy patients using PPI, in addition to
exploring patient experiences, burden of symptoms, priorities, and
knowledge of nutritional priorities in cancer. The PPI outcomes
will also aid to inform the design and development of a future
novel cohort study.
Methods: Using participatory research (PPI), six adults aged 26e70
years who have received CAR T-cell therapy in the past two years,
participated in one-to-one interviews. The interview questions
were focused on the aims of identifying patient recommendations
regarding clinical outcome measures of interest, their relevance to
patient's experience of CAR T-cell therapy, and optimal design of
the future cohort research protocol
